Gabapentin has been accepted worldwide as a novel antiepileptic drug with a favourable tolerability profile. However, movement disorders have been reported previously as rare side-effects in individual patients.
INTRODUCTION
Gabapentin (GBP) has been introduced and marketed in several countries worldwide as an additional antiepileptic drug (AED) for treatment of intractable localization-related epilepsies. Beyond its proven efficacy, its very favourable safety and tolerability profile has been emphasized repeatedly. Several authors have reported movement disorders as rare GBP-specific side-effects which included dystonia, myoclonus, and choreoathetotic movements'**. Although the comparatively low risk of adverse treatment effects under GBP3s4 is consistent with our clinical experiences in most patients, dose-independent and almost selective ataxia occurred in two of our patients which abruptly disappeared after discontinuation of GBP and which appeared to represent a further unusual but specific idiosyncratic adverse reaction to GBP.
CASE REPORTS Case 1
This 28-year-old female had suffered from drugresistant localization-related epilepsy with epigastric auras, complex-partial and secondary generalized seizures since the age of 11. Monotherapies with slow-release carbamazepine up to 2800 mg/day and with phenytoin up to 500 mglday had been shown not to be satisfactory since the seizure frequency remained stable at around 10 complex-partial seizures/month. Various drug combinations tried included carbamazepine and phenytoin as well as carbamazepine combined with valproate, phenobarbitone, lamotrigine and vigabatrin, respectively. We therefore decided to add GBP to the established monotherapy with carbamazepine. Gabapentin was started with a daily dose of 300 mg/day. In spite of this cautious regimen, the patient presented with severe gait and postural ataxia without considerable additional neurotoxic symptoms the day after introduction of GBP. The ataxia was so prominent that the patient was not able to move without help and would fall repeatedly. Since no other interfering factor became obvious, we discontinued GBP after one week with complete loss of all ataxic symptoms within 1 day.
Case 2
This 24-year-old male had presented to our epilepsy unit as an outpatient referral because of drug-resistant epilepsy. Previous unsatisfactory drug treatment had 1059-l 31 l/97/060503 + 02 $12.0010 @ 1997 British Epilepsy Association included monotherapies with carbamazepine and valproate as well as the combination of these two AEDs. Due to sedative effects of the drug, the patient had discontinued carbamazepine two weeks before he was referred. On referral he presented with up to six complex-partial seizures a day which indicated electroclinical findings of video-EEG originating from the frontal lobe. The aetiology remained unclear since early history and neuroimaging with magnetic resonance imaging (MRI) and single photon emission computer tomography gave no hints in this respect. However, MRI revealed cerebellar atrophy mainly of the vermis which corresponded well with the patient's slight gait ataxia in spite of his medication-free status at referral. Since rapid initiation of AED treatment was as necessary as a well-tolerated regimen we decided not to try phenytoin, which would have been the first choice without the patient's cerebellar symptoms, but to establish treatment with GBP due to its favourable safety profile. Under the starting dose with 300 mg/day he developed marked cerebellar symptoms including massive gait ataxia, dysarthric speech and nystagmus as the most prominent findings. As seizure frequency clearly declined, GBP was continued for 5 days. However, cerebellar symptoms continued to the extent that we had to replace GBP treatment rapidly. Under monotherapy with lamotrigine on day 6 and 1 day after abrupt discontinuation of GBP, marked amelioration was apparent. A day later the previous status had been regained, although lamotrigine had been increased to 200 mg/day.
DISCUSSION
Recent posturographic recordings in healthy volunteers gave evidence for consistent increases of bodysway velocity and amplitude after a single oral dose of 1200 mg of GBP which was indicative of a specific drug-related effect since comparable effects were not
